Close
NIHR Statistics Group
Search NIHR website
Menu

Early phase clinical trials

Early phase studies are often designed and implemented without substantive statistical input. The 3+3 maximum tolerated dose finding design being a classic example. This group aims to improve statistical aspects of early phase studies, by bridging the gap between clinical trialists using traditional designs and modern statistical methodologists with many improvements to offer.

We are interested in reaching a consensus within the statistical community of which modern methods should be regarded as standard. We aim to communicate these methods to a wider audience through training and education to increase their use in real-life trials.

Collaborative research enables us to consolidate our knowledge and share expertise. Our research section seeks to undertake collaborative working to promote high quality research by tackling discipline specific issues.

If you would like to join a working group committee or wish to find out more, please email the NIHR Statistics Group.

Group leaders

  • Pavel Mozgunov

    University of Cambridge

  • Christina Yap

    The Institute of Cancer Research

Committee members

  • Aimee Jackson

    University of Birmingham

  • Emily Alger

    The Institute of Cancer Research

  • Haiyan Zheng

    University of Bath

  • Simon Bond

    Cambridge Clinical Trials Unit

Former leaders and members

  • Simon Bond

Publications

Past events